Press Release – BioMark Continues to Strengthen its Intellectual Property position With New Patent
and Trademark Use in Canada
![biomark diagnostics patent](https://www.biomarkdiagnostics.com/wp-content/uploads/2022/06/biomark-diagnostics-patent.jpg)
BioMark Continues to Strengthen its Intellectual Property position With New Patent and Trademark Use in Canada Vancouver, British Columbia – (June 21st, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company developing molecular diagnostic tests with a focus on hard to detect and […]
BioMark Receives European Patent for Cancer Diagnostic
![biomark receives european patent for cancer diagnostic](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/biomark-receives-european-patent-for-cancer-diagnostic.jpg)
Vancouver, British Columbia – (June 18, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announced today that the company has been granted a patent titled “A METHOD FOR ASSAYING THE ACTIVITY OF SPERMIDINE/SPERMINE N1-ACETYLTRANSFERASE.” The method comprises correlating a presence of the acetylated metabolite of rimantadine or tocainide to spermidine/spermine N1-acetyltransferase […]